Biochem/physiol Actions

Reversible: yes

Product competes with ATP.

Target IC₅₀: 7 nM, 20 nM, 1.3 nM, 700 pM, 8.5 nM, against protein kinase A , CaM kinase, myosin light chain kinase, protein kinase C, and protein kinase G, respectively

Cell permeable: yes

Primary TargetPKA

General description

A potent, cell-permeable broad spectrum inhibitor of protein kinases. Inhibits CaM kinase (IC₅₀ = 20 nM), myosin light chain kinase (IC₅₀ = 1.3 nM), protein kinase A (IC₅₀ = 7 nM), protein kinase C (IC₅₀ = 0.7 nM), and protein kinase G (IC₅₀ = 8.5 nM). Also inhibits platelet aggregation induced by collagen or ADP but has no effect on thrombin-induced platelet aggregation. Induces apoptosis in human malignant glioma cell lines. Arrests normal cells at the G₁ checkpoint.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Couldwell, W.T., et al. 1994. FEBS Lett.345, 43.Nishimura, H. and Simpson, I.A. 1994. Biochem. J.302, 271.Bruno, S., et al. 1992. Cancer Res.52, 470.Kiss, Z. and Deli, E. 1992. Biochem. J.288, 853.Vitale, M.L., et al. 1992. Neuroscience51, 463.Hoffman, R. and Newland, E.S. 1991. Cancer Chemotherap. Pharmacol.28, 102.Oka, S., et al. 1986. Agric. Biol. Chem.50, 2723.

Packaging

Packaged under inert gas

100 µg in Plastic ampoule

Physical form

A 1 mM (100 µg/214 µl) solution of Staurosporine (Cat. No. 569397) in DMSO.

Reconstitution

Following initial thaw, aliquot, purge with inert gas, and freeze (-70°C).

Warning

Toxicity: Irritant (B)